Gamma oryzanol, a rice bran compound sold as a supplement and licensed in Japan as a medicine, is used to lower cholesterol and ease menopausal complaints. Evidence is thin: the cholesterol effect is unconfirmed, menopausal relief lacks accessible support from inactive-comparison trials, and muscle and hormone claims have not held up consistently. Risks look mild. For health-focused adults it is a low-risk, low-certainty option whose effects, if present, appear modest. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL cholesterol | Below 160 mg/dL | Main claimed benefit |
| Triglycerides | Below 150 mg/dL | Fell with fortified oil |
| HbA1c | Below 5.7% | Expected to change in diabetes or prediabetes |
| ALT and AST | ALT about 7–56 U/L; AST about 10–40 U/L | Label lists liver-enzyme rises |
| TSH | 0.4–4.0 mIU/L | Can be lowered in hypothyroidism |
| Free thyroxine | Not specified in the ER | Paired with TSH in thyroid disease |
| Home blood pressure | Not specified in the ER | Label lists blood-pressure rise |
Cadence: Baseline before starting; lipids, liver enzymes and blood pressure at 8–12 weeks, then every 6–12 months; HbA1c at 12 weeks, then every 6 months; TSH with free thyroxine 6–8 weeks after starting in anyone taking levothyroxine